Tsai John

Tsai John is listed in filings as Director at Blueprint Medicines Corporation. This profile follows SEC Form 4 activity through Jul 21, 2025, including 6 public disclosures. Recent filings connect the profile to Blueprint Medicines Corporation (BPMC). The current snapshot covers public activity from Jun 24, 2025 to Jul 21, 2025. Reported amounts are shown as $485.1K to $337.4K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.